Results 151 to 160 of about 36,345 (262)

Precision Targeting in Metastatic Castration-Resistant Prostate Cancer: Advancements in Personalized Therapeutics

International Journal of Medical Students
Background:  Castration-resistant prostate cancer continues to be an incurable and aggressive condition. Enzalutamide; an antiandrogen, shows better radiographic progression-free survival and overall survival in men with metastatic castration ...
ALI HASSAN SALIM KIDIYA, Arshiya ummey, Naga Sai Gouthami Gurujala, Srijamya   +3 more
doaj  

Metastasis of Castration-Resistant Prostate Adenocarcinoma to the Lacrimal Gland: A Case Report. [PDF]

Reports (MDPI)
Milic N, Lojanica MV, Ivanovic M, Matijasevic M, Ivanovic S.   +4 more
europepmc   +1 more source

Cyclins and Cyclin‐Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer

MedComm, Volume 7, Issue 9, September 2026.
This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng, Zhipeng Shen, Yuanfang Wu, Xingze Huang, Zhongyuan Zhang, Jiangyu Liu, Qichun Wei, Wenhao Chen, Ye Chen, Liang Xu   +9 more
wiley   +1 more source

Improved Chemosensitivity in Metastatic Castration-Resistant Prostate Cancer: The Synergistic Effects of S-Adenosylmethionine and Cabazitaxel. [PDF]

Cancer Med
Arpino R, Cadoni F, Pagano C, Coppola L, Del Vecchio V, Nigam A, Mosca L, Porcelli M.   +7 more
europepmc   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Immunotherapy in metastatic castration-resistant prostate cancer: transformative for the few, not for all. [PDF]

Transl Androl Urol
de Souza VPB, Barata PC.
europepmc   +1 more source

Oxysterols in Cancer: From Biosynthesis and Pathophysiology to Targeted Therapeutics

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Mechanisms by which oxysterol targeting may enhance immunotherapy efficacy. This figure illustrates potential metabolic interventions that may improve antitumor immunity by modulating oxysterol related pathways. CH25H modulation may reduce 25‐HC accumulation, promote the conversion of cold tumors into hot tumors, and increase T cell infiltration and PD‐
Haili Shang, Yongsheng Li
wiley   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer. [PDF]

Mol Oncol
Gordon N, Gallagher PT, Richter OI, Poudel Neupane N, Mandigo AC, McCann JJ, Dylgjeri E, Vasilevskaya I, McNair C, Paller CJ, Kelly WK, Knudsen KE, Schiewer MJ, Shafi AA.   +13 more
europepmc   +1 more source

Total synthesis and structural characterization of a novel protein scaffold from the snail Biomphalaria glabrata

Protein Science, Volume 35, Issue 9, September 2026.
Abstract Disulfide‐rich miniproteins constitute compact and highly stable scaffolds of growing interest for molecular and structural engineering. Schistosomins are ~80‐residue proteins conserved across gastropods that form a long‐standing orphan family whose structure and biological roles have remained unknown.
Oleg Melnyk, Stéphanie Caby, Armelle Vigouroux, Christine Demanche, Rémi Desmet, Magalie Sénéchal, Benoît Snella, Alexandra Mougel, Céline Boidin‐Wichlacz, Aurélie Parmentier, Ugo Pasco, Sonia Cantel, Solange Moréra, Jérôme Vicogne   +13 more
wiley   +1 more source

Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer.

JAMA Netw Open
Ozay ZI, Jo Y, Gebrael G, Ostrowski M, Mathew Thomas V, Li H, Graf RP, Roy S, Maughan BL, Guha A, Riaz IB, Antonarakis ES, McKay RR, Agarwal N, Swami U.   +14 more
europepmc   +1 more source